3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Neuroendocrine Tumors
2
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Paclitaxel
3
fosbretabulin
2
dabrafenib
2
combretastatin
2
Carboplatin
2
trametinib
1
tislelizumab
1
surufatinib
1
spartalizumab
1
lenvatinib
1
efatutazone
1
PLX8394
1
CCT239065
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thyroid Carcinoma, Anaplastic
×
fosbretabulin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn